Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize

April 19, 2013

Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.

The study, conducted at Massachusetts General Hospital in Boston, included 156 patients with proven renal cell cancer. Clear cell renal carcinoma contains microscopic areas of fat, which is not seen on conventional imaging, said Dr. Azadeh Elmi, lead author of the study. "Chemical shift MRI enables us to quantify even small amounts of fat," she said. The study found that chemical shift MRI was about 83% accurate in differentiating clear cell from other types of kidney cancer.

Clear cell type is the most common type of kidney cancer, and it has the greatest potential to metastasize, said Dr. Elmi. Chemical shift MRI is a protocol that can be readily performed in kidney MRI at no additional cost, she said. "As we are moving toward less invasive treatment strategies for cancer patients, the need to better distinguish tumor characteristics is becoming greater. This study demonstrates that MRI is a promising tool in characterization before planning treatment. The surgeons can get better insight of the and can plan before hand," Dr. Elmi said.

The study will be presented April 19 during the ARRS Annual Meeting in Washington, DC.

Explore further: FDA clears Pfizer drug for advanced kidney cancer

Related Stories

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Molecular imaging signals new treatment protocol for kidney cancer

June 11, 2012
Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone ...

Cancer-seeking 'smart bombs' target kidney cancer cells

June 6, 2011
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy ...

Black patients with kidney cancer have poorer survival than whites

November 12, 2012
Among patients with the most common form of kidney cancer, whites consistently have a survival advantage over blacks, regardless of patient and tumor characteristics or surgical treatment. That is the conclusion of a new ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.